Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

YC‐1 inhibits proliferation of breast cancer cells by down‐regulating EZH2 expression via activation of c‐Cbl and ERK
Ling‐Chu Chang, Hui‐Yi Lin, M. Tsai, et al.
British Journal of Pharmacology (2014) Vol. 171, Iss. 17, pp. 4010-4025
Open Access | Times Cited: 35

Showing 1-25 of 35 citing articles:

Recent advancements in the development of bioactive pyrazoline derivatives
Bhupender Nehra, Sandeep Rulhania, Shalini Jaswal, et al.
European Journal of Medicinal Chemistry (2020) Vol. 205, pp. 112666-112666
Closed Access | Times Cited: 113
Regulation of EZH2 protein stability: new mechanisms, roles in tumorigenesis, and roads to the clinic
Yunyun Guo, Rui Cheng, Yuqing Wang, et al.
EBioMedicine (2024) Vol. 100, pp. 104972-104972
Open Access | Times Cited: 15
EZH2 inhibits autophagic cell death of aortic vascular smooth muscle cells to affect aortic dissection
Rui Li, Xin Yi, Wei Xiang, et al.
Cell Death and Disease (2018) Vol. 9, Iss. 2
Open Access | Times Cited: 79
The decrease in histone methyltransferase EZH2 in response to fluid shear stress alters endothelial gene expression and promotes quiescence
Monika Maleszewska, Byambasuren Vanchin, Martin C. Harmsen, et al.
Angiogenesis (2015) Vol. 19, Iss. 1, pp. 9-24
Open Access | Times Cited: 72
YC-1 induces G0/G1phase arrest and mitochondria-dependent apoptosis in cisplatin-resistant human oral cancer CAR cells
Miau-Rong Lee, Chingju Lin, Chi‐Cheng Lu, et al.
Biomedicine (2017) Vol. 7, Iss. 2, pp. 12-12
Open Access | Times Cited: 69
Post-translational modifications of EZH2 in cancer
Zhongwei Li, Minle Li, Diandian Wang, et al.
Cell & Bioscience (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 69
Pyrazoline Containing Compounds as Therapeutic Targets for Neurodegenerative Disorders
Mohamed Jawed Ahsan, Amena Ali, Abuzer Ali, et al.
ACS Omega (2022) Vol. 7, Iss. 43, pp. 38207-38245
Open Access | Times Cited: 37
Enhancer of zeste homolog 2 silencing inhibits tumor growth and lung metastasis in osteosarcoma
Yangfan Lv, Guangning Yan, Gang Meng, et al.
Scientific Reports (2015) Vol. 5, Iss. 1
Open Access | Times Cited: 53
The molecular mechanisms and therapeutic potential of EZH2 in breast cancer
Sara Adibfar, Marischa Elveny, Hadisha Sh. Kashikova, et al.
Life Sciences (2021) Vol. 286, pp. 120047-120047
Closed Access | Times Cited: 33
Advances in antitumor research of HIF-1α inhibitor YC-1 and its derivatives
Chenglin Ouyang, Jing Zhang, Xiaoyong Lei, et al.
Bioorganic Chemistry (2023) Vol. 133, pp. 106400-106400
Closed Access | Times Cited: 15
HIF-1α inhibitor YC-1 suppresses triple-negative breast cancer growth and angiogenesis by targeting PlGF/VEGFR1-induced macrophage polarization
Yan Li, Mengzhao Zhang, Shujing Zhang, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 161, pp. 114423-114423
Open Access | Times Cited: 15
Regulation and role of post-translational modifications of enhancer of zeste homologue 2 in cancer development.
Haiqi Lu, Guangliang Li, Chenyi Zhou, et al.
PubMed (2016) Vol. 6, Iss. 12, pp. 2737-2754
Closed Access | Times Cited: 42
EWS/FLI1 Characterization, Activation, Repression, Target Genes and Therapeutic Opportunities in Ewing Sarcoma
Muhammad Yasir, Jin‐Young Park, Wanjoo Chun
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 20, pp. 15173-15173
Open Access | Times Cited: 11
Resveratrol inhibits the proliferation of estrogen receptor-positive breast cancer cells by suppressing EZH2 through the modulation of ERK1/2 signaling
Chunyan Hu, Yun Liu, Mengying Teng, et al.
Cell Biology and Toxicology (2019) Vol. 35, Iss. 5, pp. 445-456
Closed Access | Times Cited: 35
Soluble Guanylate Cyclase Stimulators and Activators: Where are We and Where to Go?
Si-Jia Xiao, Qianbin Li, Liqing Hu, et al.
Mini-Reviews in Medicinal Chemistry (2019) Vol. 19, Iss. 18, pp. 1544-1557
Closed Access | Times Cited: 30
Pharmacophore hybridization approach to discover novel pyrazoline-based hydantoin analogs with anti-tumor efficacy
Neha Upadhyay, Kalpana Tilekar, Fulvio Loiodice, et al.
Bioorganic Chemistry (2020) Vol. 107, pp. 104527-104527
Closed Access | Times Cited: 29
Synthesis and Evaluation of New Pyrazoline Derivatives as Potential Anticancer Agents in HepG-2 Cell Line
Weijie Xu, Ying Pan, Hong Wang, et al.
Molecules (2017) Vol. 22, Iss. 3, pp. 467-467
Open Access | Times Cited: 29
A HIF-1α inhibitor combined with palmitic acid and L-carnitine treatment can prevent the fat metabolic reprogramming under hypoxia and induce apoptosis in hepatocellular carcinoma cells
Shohei Matsufuji, Yoshihiko Kitajima, Kazuki Higure, et al.
Cancer & Metabolism (2023) Vol. 11, Iss. 1
Open Access | Times Cited: 8
Prolyl Hydroxylase Inhibition Enhances Liver Regeneration Without Induction of Tumor Growth
Jonathan M. Harnoss, Lisa Katharina Platzer, Jürgen Burhenne, et al.
Annals of Surgery (2016) Vol. 265, Iss. 4, pp. 782-791
Closed Access | Times Cited: 22
The role of CBL family ubiquitin ligases in cancer progression and therapeutic strategies
Jiaqi Ren, Linlin Lv, Xufeng Tao, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 2
Synthesis and structure-activity relationship studies of novel 3,9-substituted α-carboline derivatives with high cytotoxic activity against colorectal cancer cells
Yi-Chien Lin, Yi‐Fong Chen, Li-Shin Tseng, et al.
European Journal of Medicinal Chemistry (2016) Vol. 110, pp. 98-114
Open Access | Times Cited: 18
EZH2 inhibition sensitizes tamoxifen‑resistant breast cancer cells through cell cycle regulation
Si Chen, Fan Yao, Qinghuan Xiao, et al.
Molecular Medicine Reports (2017)
Open Access | Times Cited: 16
Reciprocal interaction of HOTAIR and SP1 together enhance the ability of Xiaoji decoction and gefitinib to inhibit EP4 expression
Jingjing Wu, Qing Tang, Xiaolin Ren, et al.
Journal of Ethnopharmacology (2019) Vol. 237, pp. 128-140
Closed Access | Times Cited: 13
Targeting EGFR by Newer 1-(3,5-Bis((E)-4-hydroxy-3-methoxystyryl)-1H-pyrazol-1-yl)-2-((substituted phenyl)amino)ethan-1-one Analogues for the Treatment of Cancer: Synthesis, In-vitro and In-silico Studies
Menshawy A. Mohamed, Abuzer Ali, Amena Ali, et al.
Journal of Molecular Structure (2024) Vol. 1315, pp. 138826-138826
Closed Access | Times Cited: 1
Hypoxia‑inducible factor-1 signaling pathway influences the sensitivity of HCC827 cells to gefitinib
Qian Jin, Jianying Zhou, Xianrong Xu, et al.
Oncology Letters (2019)
Open Access | Times Cited: 8
Page 1 - Next Page

Scroll to top